AU2011322147A1 - Formulations and methods for attenuating respiratory depression induced by opioid overdose - Google Patents

Formulations and methods for attenuating respiratory depression induced by opioid overdose Download PDF

Info

Publication number
AU2011322147A1
AU2011322147A1 AU2011322147A AU2011322147A AU2011322147A1 AU 2011322147 A1 AU2011322147 A1 AU 2011322147A1 AU 2011322147 A AU2011322147 A AU 2011322147A AU 2011322147 A AU2011322147 A AU 2011322147A AU 2011322147 A1 AU2011322147 A1 AU 2011322147A1
Authority
AU
Australia
Prior art keywords
naltrexone
opioid
formulation
respiratory depression
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011322147A
Other languages
English (en)
Inventor
Veeraindar Goli
Michael J. Lamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpharma Pharmaceuticals LLC
Original Assignee
Alpharma Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals LLC filed Critical Alpharma Pharmaceuticals LLC
Publication of AU2011322147A1 publication Critical patent/AU2011322147A1/en
Priority to AU2015264939A priority Critical patent/AU2015264939A1/en
Priority to AU2017213491A priority patent/AU2017213491A1/en
Priority to AU2019201397A priority patent/AU2019201397A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011322147A 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose Abandoned AU2011322147A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2015264939A AU2015264939A1 (en) 2010-10-26 2015-12-07 Formulations and methods for attenuating respiratory depression induced by opioid overdose
AU2017213491A AU2017213491A1 (en) 2010-10-26 2017-08-09 Formulations and methods for attenuating respiratory depression induced by opioid overdose
AU2019201397A AU2019201397A1 (en) 2010-10-26 2019-02-27 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
US61/406,752 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015264939A Division AU2015264939A1 (en) 2010-10-26 2015-12-07 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Publications (1)

Publication Number Publication Date
AU2011322147A1 true AU2011322147A1 (en) 2013-04-18

Family

ID=45470606

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011322147A Abandoned AU2011322147A1 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Country Status (14)

Country Link
US (3) US20140030343A1 (enExample)
EP (1) EP2632442A2 (enExample)
JP (1) JP2013540807A (enExample)
KR (3) KR20160017668A (enExample)
CN (1) CN103189055A (enExample)
AU (1) AU2011322147A1 (enExample)
BR (1) BR112013009267A2 (enExample)
CA (1) CA2814230A1 (enExample)
IL (1) IL225966A0 (enExample)
MX (1) MX2013003832A (enExample)
RU (1) RU2541159C2 (enExample)
SG (1) SG189234A1 (enExample)
WO (1) WO2012056402A2 (enExample)
ZA (1) ZA201302363B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CA2814230A1 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
EP2670400A1 (en) * 2011-02-02 2013-12-11 Alpharma Pharmaceuticals LLC Pharmaceutical composition comprising opioid agonist and sequestered antagonist
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
KR102688278B1 (ko) 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3032996C (en) 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
IL273627B2 (en) 2017-12-20 2025-03-01 Purdue Pharma Lp Morphine sulfate dosage forms for abuse deterrence
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023081185A1 (en) * 2021-11-02 2023-05-11 Enalare Therapeutics Inc. Methods of treating respiratory depression modulated by a non-opioid agent
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914818B2 (en) * 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
CN1901954B (zh) * 2003-12-05 2013-01-16 康尔福盛303有限公司 借助病人监测系统的病人自控镇痛技术
CN101321686A (zh) 2005-10-07 2008-12-10 佛罗里达大学研究基金会有限公司 用于多路信号传递和光编码的多组分纳米颗粒
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
AU2008296905A1 (en) * 2007-09-04 2009-03-12 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
BRPI0911715A2 (pt) 2008-07-31 2019-09-24 Alma Mater Studiorum - Universita' Di Bologna partículas ativas para aplicações bio-analíticas e métodos para sua preparação.
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
CA2814230A1 (en) * 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose

Also Published As

Publication number Publication date
CA2814230A1 (en) 2012-05-03
KR20170102571A (ko) 2017-09-11
WO2012056402A3 (en) 2012-10-04
US20140030343A1 (en) 2014-01-30
ZA201302363B (en) 2014-06-25
JP2013540807A (ja) 2013-11-07
CN103189055A (zh) 2013-07-03
US20160045449A1 (en) 2016-02-18
KR20160017668A (ko) 2016-02-16
SG189234A1 (en) 2013-05-31
RU2013117274A (ru) 2014-12-10
KR20130097211A (ko) 2013-09-02
US20170367987A1 (en) 2017-12-28
IL225966A0 (en) 2013-06-27
BR112013009267A2 (pt) 2016-07-26
RU2541159C2 (ru) 2015-02-10
WO2012056402A2 (en) 2012-05-03
MX2013003832A (es) 2013-10-01
EP2632442A2 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
US20170367987A1 (en) Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
US8623418B2 (en) Pharmaceutical composition
US20200155543A1 (en) Abuse resistant transmucosal drug delivery device
US7034036B2 (en) Inhibitors of ABC drug transporters at the blood-brain barrier
US20030191147A1 (en) Opioid antagonist compositions and dosage forms
WO2001085257A2 (en) Opioid antagonist compositions and dosage forms
US20130122065A1 (en) Pharmaceutical Composition
US20150104519A1 (en) Pharmaceutical Compositions
WO2009085778A1 (en) Pharmaceutical composition
AU2001259458A1 (en) Opioid antagonist compositions and dosage forms
US20190290622A1 (en) Compositions and Methods for Treating Opioid Overdose and Opioid Abuse
AU2008338439A1 (en) Pharmaceutical composition
US20210059944A1 (en) Novel dosage form
AU2019201397A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
HK1186970A (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
AU2014216032B2 (en) Pharmaceutical composition
AU2019202760A1 (en) Pharmaceutical composition
AU2014216026A1 (en) Pharmaceutical composition
CA2427330A1 (en) Inhibitors of abc drug transporters at the blood-brain barrier

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted